Personal information

Biography

Fatih M. Uckun, M.D., Ph.D, is an Active Member of the American Society for Clinical Investigation (ASCI), an honor society for physician-scientists, and an active member of several professional organizations, including ASCO and AACR. He is a Principal Member of the Turkish Academy of Sciences TUBA ((a Member of the European Federation of Academies of Sciences and Humanities/ALLEA and Association of Academies and Societies of Sciences in Asia/AASSA). He earned his doctoral degrees at University of Heidelberg in Germany and completed his residency training in Pediatrics, fellowship training in Hematology/Oncology/Blood and Bone Marrow Stem Cell Transplantation, as well as postdoctoral research training in immunology at the University of Minnesota in the US. Dr. Uckun has more than 30 years of professional experience in developmental therapeutics and biopharmaceuticals in oncology/immuno-oncology as well as infectious diseases and immunology.

Dr. Uckun worked 11 years as a Professor of Bone Marrow Transplantation, Therapeutic Radiology-Radiation Oncology, Pharmacology, and Pediatrics as well as Director of the Biotherapy Institute at the University of Minnesota, where he became the first recipient of the Endowed Hughes Chair in Biotherapy. He worked 6 years as a Professor and Head of Translational Research in Leukemia and Lymphoma of the CCBD and a Principal Investigator of the Stem Cell-Regenerative Medicine Initiative at the at the University of Southern California. He has held executive positions in multiple biotechnology companies and has extensive regulatory experience. He has published more than 500 peer-reviewed papers and he has authored numerous review articles and book chapters. He received numerous awards including the Stohlman Memorial Award of the Leukemia Society of America (now known as the Leukemia and Lymphoma Society/LLS), the highest honor given to a Leukemia Society Scholar. He is the recipient of the 2018-2019 Academic Prize in Health and Life Sciences awarded by TUBA. He has served as a member of several editorial boards and NIH grant review/special emphasis panels.

In addition, Dr. Uckun has deep knowledge and 20+ years of experience in treatment of infectious diseases and their complications. In particular, he has extensive experience in viral, fungal, and bacterial infections of immunocompromised hosts, septic shock, ARDS as well as systemic capillary leak syndrome and cytokine release syndrome (CRS). He served as a Defense Advanced Research Projects Agency (DARPA) PI and directed a universal virus neutralizer program project as part of a countermeasures initiative against viruses that can be used as bioweapons.

Activities

Employment (10)

Ares Pharmaceuticals LLC: Saint Paul, MN, US

2015-07-15 to present | Chief Medical Officer
Employment
Source: Self-asserted source
Fatih M. Uckun

Oncotelic Inc: Agoura Hills, CA, US

2022-05-01 to 2023-02-28 | Chief Medical Officer (CONSULTANT )
Employment
Source: Self-asserted source
Fatih M. Uckun

Reven Pharmaceuticals: Golden, CO, US

2020-06-26 to 2022-03-01 | Chief Medical Officer and Chief Scientific Officer
Employment
Source: Self-asserted source
Fatih M. Uckun

Aptevo Therapeutics (United states): Seattle, Washington, US

2021-04 to 2021-12-31 | Consultant and Chief Clinical Advisor
Employment
Source: Self-asserted source
Fatih M. Uckun

Worldwide Clinical Trials: Morrisville, NC, US

2020-01-01 to 2020-06-25 | Vice President
Employment
Source: Self-asserted source
Fatih M. Uckun

Mateon Therapeutics Inc: South San Francisco, CA, US

2019-01-01 to 2020-01-01 | Chief Medical Officer
Employment
Source: Self-asserted source
Fatih M. Uckun

Syneos Health Inc: Morrisville, NC, US

2017-09-25 to 2018-11-15 | Executive Medical Director
Employment
Source: Self-asserted source
Fatih M. Uckun

University of Southern California: Los Angeles, CA, US

2009-07-01 to 2015-06-30 | Professor (Keck School of Medicine)
Employment
Source: Self-asserted source
Fatih M. Uckun

Drug Discovery Enterprises: St. Paul, Minnesota, US

1995-07-01 to 2008-07-01 | President and Director
Employment
Source: Self-asserted source
Fatih M. Uckun

University of Minnesota: Minneapolis, Minnesota, US

1984-05-15 to 1997-07-30 | Professor (Academic Health Center)
Employment
Source: Self-asserted source
Fatih M. Uckun

Education and qualifications (2)

University of Minnesota: Minneapolis, Minnesota, US

1984 to 1992 | Residency Training in Pediatrics, Fellowsip Training in Hematology/Oncology/Blood and Bone Marrow Transplantation, Postdoctoral Fellowship in Immunology and Microbiology
Qualification
Source: Self-asserted source
Fatih M. Uckun

University of Heidelberg: Heidelberg, DE

1977 to 1984 | MD; PhD
Education
Source: Self-asserted source
Fatih M. Uckun

Professional activities (8)

Turkish Academy of Sciences: Çankaya, TR

Member
Distinction
Source: Self-asserted source
Fatih M. Uckun

Turkish Academy of Sciences: Çankaya, TR

Membership
Source: Self-asserted source
Fatih M. Uckun

The American Society for Clinical Investigation: Ann Arbor, MI, US

Senior Member
Distinction
Source: Self-asserted source
Fatih M. Uckun

American Society of Hematology: Washington, DC, US

Membership
Source: Self-asserted source
Fatih M. Uckun

American Society of Clinical Oncology: Alexandria, VA, US

Membership
Source: Self-asserted source
Fatih M. Uckun

American Association for Cancer Research: PA, PA, US

Membership
Source: Self-asserted source
Fatih M. Uckun

The American Society for Clinical Investigation: Ann Arbor, MI, US

1996 to present
Membership
Source: Self-asserted source
Fatih M. Uckun

University of Minnesota: Minneapolis, MN, US

1996 | Endowed Highes Chair in Biotherapy (Academic Health Center)
Distinction
Source: Self-asserted source
Fatih M. Uckun

Funding (13)

Amplifying Radiation Potency Against Leukemic Stem Cells

2012-07-06 to 2014-06-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R21CA164098
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL

2011-04-01 to 2016-03-31 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R01CA154471
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

Targeting SYK Kinase in B-Lineage ALL with CD19-Specific C-61 Nanoparticles

2010-09-01 to 2016-07-31 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: U01CA151837
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

TXU-PAP FOR THE TREATMENT OF AIDS

1999-05-01 to 2002-04-30 | Grant
National Institute of Allergy and Infectious Diseases (Bethesda, US)
GRANT_NUMBER: R01AI044671
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

CANCER THERAPY WITH BIOTHERAPEUTICS CONTAINING GENISTEIN

1996-09-30 to 2000-08-31 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: U01CA072157
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

PROTEIN TYROSINE KINASES AND ELECTROMAGNETIC FIELDS

1995-04-01 to 1999-08-31 | Grant
National Institute of Environmental Health Sciences (Durham, US)
GRANT_NUMBER: R01ES007175
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

B43 (ANTI-CD19)-POKEWEED ANTIVIRAL PROTEIN IMMUNOTOXIN

1993-09-30 to 1997-07-28 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: U01CA061549
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

PROGNOSIS OF NEWLY DIAGNOSED AND RELAPSED ALL

1993-09-01 to 1997-06-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: U01CA060437
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

IMMUNOBIOLOGY OF NORMAL AND LEUKEMIC B-CELL PRECURSORS

1990-01-01 to 1992-12-31 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R01CA051425
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

RADIOCHEMOSENSITIVITY OF LEUKEMIC PROGENITOR CELLS

1986-07-01 to 1997-04-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R01CA042111
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

BIOLOGICAL AND PHYSICAL FACTORS IN TBI

1986-07-01 to 1994-06-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R01CA042633
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

RADIOCHEMOSENSITIVITY OF LEUKEMIC PROGENITOR CELLS

1986-07-01 to 1992-04-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R29CA042111
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard

RADIOCHEMOSENSITIVITY OF LEUKEMIC PROGENITOR CELLS

1986-07-01 to 1989-06-30 | Grant
National Cancer Institute (Rockville, US)
GRANT_NUMBER: R23CA042111
Source: Self-asserted source
Fatih M. Uckun via DimensionsWizard